trending Market Intelligence /marketintelligence/en/news-insights/trending/90-tIe6xEOQOv_XRAuxdWQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Biotechnology company Monopar Therapeutics closes $10.2M Nasdaq IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Biotechnology company Monopar Therapeutics closes $10.2M Nasdaq IPO

Monopar Therapeutics Inc. closed its IPO on the Nasdaq Global Market to raise about $10.2 million in gross proceeds.

The Wilmette, Ill.-based biotechnology company sold 1,277,778 common shares at $8 apiece in the IPO.

Monopar's shares started trading on the exchange Dec. 19 under the ticker symbol MNPR.

The company, which develops treatments for cancer patients, previously said it plans to use the proceeds to advance its global phase 3 trial for Validive, a potential treatment for a complication arising from chemotherapy or radiotherapy in patients with oropharyngeal cancer.

Additionally, the funds raised will be used for a phase 2 study of camsirubicin and development of MNPR-101.

Chandler Robinson is CEO and a director of Monopar, which he co-founded in 2014. Tactic Pharma, LLC is among shareholders of Monopar.

JonesTrading Institutional Services LLC was the lead book-running manager for the IPO, while Brookline Capital Markets was the co-manager.